KIF5B and non-small cell lung carcinoma: In stark contrast, in a study of NSCLC patients confirmed to be ALK‐positive via immunohistochemistry and fluorescence in situ hybridization, those carrying fusions with one of the three most common partners (EML4, KIF5B, and HIP1) constituted 86.1% of (136/158) cases.38